Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab for vascular and splenic inflammation in moderate-to-severe psoriasis
2017-003697-14Phase 4Terminated
- Sponsor
- Aarhus University Hospital
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in plaque psoriasis and psoriasis comparing Brodalumab with Placebo (2 arms). Primary endpoint: Change in aortic MeanTBRmax from baseline to week 16. Started Sep 2017; status: terminated.
02
Drugs
brodalumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2017-003697-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003697-14.